Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.33 |
| ▸ | AHCY | P23526 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.33 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.32 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4350570 | 0.88 | ADORA3 (0.47) | ADORA3ADORA1ADORA2AP2RY1TMIGD3 | |
| SCHEMBL4350587 | 0.86 | AHCY (0.43) | AHCY | |
| SCHEMBL1401951 | 0.86 | LMNA (0.41) | ADORA3AHCYALDH1A1LMNATP53 | |
| SCHEMBL12003121 | 0.86 | LMNA (0.41) | ADORA3AHCYALDH1A1LMNATP53 | |
| SCHEMBL3714471 | 0.86 | LMNA (0.41) | ADORA3AHCYALDH1A1LMNATP53 | |
| SCHEMBL239127 | 0.86 | LMNA (0.41) | ADORA3AHCYALDH1A1LMNATP53 | |
| SCHEMBL8960068 | 0.86 | LMNA (0.41) | ADORA3AHCYALDH1A1LMNATP53 | |
| SCHEMBL1401952 | 0.86 | LMNA (0.41) | ADORA3AHCYALDH1A1LMNATP53 | |
| SCHEMBL4349829 | 0.82 | ABCB1 (0.32) | ADORA3ALDH1A1LMNATP53MAPT | |
| SCHEMBL242481 | 0.81 | LMNA (0.40) | ADORA3ALDH1A1LMNATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281126-A1 | Organic Compounds | NOVARTIS AG | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281126-A1 | Organic Compounds | CYP3A43, CYP3A4, CYP2C19 | ADORA3 732/4885AHCY 4831/4885ALDH1A1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.